筛选和先导化合物优化

This application note describes the automation of low volume, high sensitivity ELISAs using OptiMax™ plates on the Freedom EVO liquid handling platform.

Degenerative eye diseases affect millions of people around the world, causing progressive loss of vision and, in some cases, complete blindness. Researchers in Australia are using stem cell technologies to investigate ways of halting, or even reversing, the effects of common eye diseases.

Antibody discovery and development company MorphoSys has a wealth of experience in designing novel assays for the screening and characterization of therapeutic antibodies. With active programs in oncology, inflammatory and autoimmune diseases, the company’s Discovery, Alliances and Technologies Department relies on a variety of automated solutions to provide the throughput necessary to support its pipeline.

The direct digital dispensing capabilities of the HP D300 are helping to identify potential new treatments for acute lymphoblastic leukemia at University Children’s Hospital Zurich. By enabling picoliter drug volumes to be dispensed straight into cell-based assay plates, the system is helping researchers to rapidly test novel drug combinations directly in patient-derived leukemia cells.

Novartis’ Drug Metabolism and Pharmacokinetics (DMPK) Biologics Division, based in Basel, Switzerland, has developed a flexible, fully automated workflow for blood serum sample preparation and ELISA processing by combining two Freedom EVO 150 workstations.

Researchers at Germany's University of Konstanz have established a fluorescence-based method for screening small molecules to identify potential antimicrobial agents. Using the Freedom EVO workstation’s MultiChannel Arm 384, the University’s Screening Center has developed an innovative technique allowing reliable liquid transfers down to 80 nanoliters.

Tecan’s Fluent® Laboratory Automation Solution is providing exceptional flexibility for small molecule screening at IME ScreeningPort in Hamburg, Germany. This groundbreaking system offers straightforward automation of complex assays, enabling both in vitro and cell-based assays to be performed on a single, compact instrument.

The Life Sciences laboratory of the Central Research Institute at Ishihara Sangyo Kaisha Ltd has used Tecan’s Freedom EVO 200 workstation to develop a successful automated protocol for efficient siRNA transfection, paving the way for efficient high throughput screening of small RNA libraries.

High throughput screening for drug discovery depends on reliable liquid handling, such as that provided by Tecan’s Freedom EVO platform. Chicago-based company SAMDI Tech has automated its proprietary label-free SAMDI technology on a Freedom EVO system, performing rapid and quantitative analysis of challenging biochemical targets.

Osaka University’s International Drug Discovery Incubation Group opened its doors to drug discovery researchers in western Japan in April 2011, providing access to high throughput technologies including Tecan’s Freedom EVO liquid handling workstations and Infinite® M1000 microplate reader.

Isogenica provides peptide, protein and antibody discovery and design services to pharmaceutical and biotechnology companies, and has invested in two Freedom EVO liquid handling platforms to increase its capacity for the selection of next generation molecules.

Merz Pharma has taken advantage of the greater flexibility and large pipetting volumes offered by the Freedom EVO workstation's MultiChannel Arm 384 to accelerate its drug discovery pipeline, eliminating the need for single concentration analysis in its screening processes.

Tecan’s MultiChannel Arm™ 384 has revolutionized the laboratory workflow in the Division of Cancer Research at the Institut de Recherches Servier, allowing scientists to simultaneously process multiple assay plates for compound screening, as well as increasing the number of compound and enzyme combinations tested per run.